* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
As a leading service provider in the field of drug discovery and research, BOC Sciences is fully competent and dedicated to serving one-stop Proteolysis Targeting Chimeric (Protac®) based molecular drug discovery which has become a promising strategy in the area of drug discovery. With a comprehensive and advanced platform, we provides Protac® In Vitro Evaluation service to customers around the world to meet new drug discovery goals.
Targeted protein degradation provides a broad prospect for drug discovery. In addition, they pose many challenges, not only the ability to find conjugates and suitable drug-like properties for Protac® methods, but also the need to transcend chance to select E3 ligase as a template for drug discovery. Once the compound is designed and synthesized, it will follow a series of in vitro evaluation analyses from drug administration to intracellular target degradation to verify the effectiveness of Protacs in the drug development phase prior to clinical trials. BOC Sciences can provide a comprehensive set of in vitro evaluation analysis to monitor the specific parameters of each stage.
The activity of Protac® directly affects its potency and the degradation of the target protein, so it is necessary to perform Protac® activity assay during its development and screening process. We offer technical services for Protac® activity assay. Our expert team has rich experience and professional technical knowledge about Protac® activity assay, and can carry out the activity detection according to the specific needs of different customers.
Oral drugs need to have the characteristics of dissolution and stability in the stomach, absorption from the intestine and systemic circulatory stability through metabolism for the first time. Protac® is usually large and does not fall within the scope outlined in the five rules. Therefore, in the chemical properties of small molecules, solubility and stability are very important to determine whether Protac® drug candidates may become potential drugs. BOC Sciences is committed to helping our customers evaluate the solubility and stability of Protac® drug candidates under different conditions.
The ubiquitination of target protein mediated by E3 ligase complex is the key determinant of target protein degradation. To evaluate the ubiquitination efficacy of target proteins caused by PRORAC candidates, BOC Sciences has developed a series of different methods to facilitate your Protac® research.
E3 ligase is a large family of connective proteins and plays a key role in protein degradation. E3 protein substrate specificity can be reprogrammed to treat diseases with effective and selective small molecular ligands targeting E3 ligases. BOC Sciences has developed a first-class platform for ligand binding determination of E3 ligase using proprietary technology. This technique uses the target protein of DNA and high sensitive qPCR readings to achieve high sensitivity (accurate ligand KD with low skin molar range) and quantitative competitive binding assay.
BOC Sciences provides high quality advanced live-cell assay platform to help customers further develop and optimize Protac® technology. Our expert team has many years of experience in live-cell assays, which can guarantee to provide customers with high efficiency and high-quality services, helping customers get lower research costs and shorter research cycles.
The degradation of pathogenic proteins is the ultimate goal of Protac®. BOC Sciences offers different types of target degradation analysis for your flexible choice (HiBiT, AlphaLISA, TR-FRET, ELISA). HiBiT cell assay can monitor the physiological level of target protein degradation and provide end point and kinetic detection.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Interested in our Service & Products?
Need detailed information?